Replies to post #546466 on NorthWest Biotherapeutics Inc (NWBO)

[Red_Right_Hand]

Claim 1 of the combo patent currently being examined states:

1. A method of treating a glioma or enhancing an anti-glioma response in a subject in need thereof comprising administering to the subject a therapeutic agent in combination with an agent that is a checkpoint inhibitor, wherein the therapeutic agent is a dendritic cell vaccine wherein the dendritic cell is pulsed with a glioma antigen and wherein the agent that is a checkpoint inhibitor is an antibody specific for PD-1, PD-L1, or a fusion protein comprising PD-1 or PD-L1 for targeting PD-L1 or PD-1, or a combination thereof.

As others have pointed out, the original claims and the specification have a lot more material that could later be used to seek broader claims, but this claim 1 is more than sufficient to capture the activity of anyone using DCVAX in combination with any PD-1 antibody, which is more than enough to capture combos with Keytruda (Merck) or Opdivo (BMS) or Libtayo (Regeneron) or Jemperli (GSK).

And before anyone tries to say otherwise, glioblastoma is a type of glioma, as described in the patent itself and otherwise known in the art (https://www.mdanderson.org/cancerwise/glioma-vs--glioblastoma--what-is-the-difference-in-these-brain-tumors-treatment-diagnosis.h00-159537378.html)